CAMP4 Therapeutics Corporation has an analyst consensus of Strong Buy, with a price target consensus of $8.36, implying a 99.05% upside from current levels. In a report released on June 10, Chardan ...
Join a team that's shaping market access strategies for innovative therapies. Lead cross-functional initiatives to enhance patient access and payer engagement, ensuring commercial success while ...
In December 2021, the FDA approved the first therapy indicated to treat primary immunoglobulin A nephropathy. Since then, ...
CG Oncology, Inc. is currently listed on NASDAQ under CGON. One share of CGON stock can currently be purchased for approximately $67.12. Is CG Oncology, Inc. listed on the NASDAQ or NYSE? CG Oncology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results